Dog · Canis lupus familiaris · typical adult weight 2.00–80.00 kg
Oclacitinib is dosed at 0.4–0.6 mg/kg PO q12h x 14 days, then q24h in dogs, per APOQUEL - Oclacitinib Maleate Tablet, Coated [US Product Label for Dogs]. Kalamazoo, MI: Zoetis Inc.; 2020. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a39a0298-6453-4c21-a3b0-01c1a52a109b — Verified against Plumb's Veterinary Drug Handbook, 10th Ed, p.976 (2026-08-01). — Plumb's 10th ed (held) printed p.947, Oclacitinib monograph spanning p.947-948; page located 2026-08-05 from the book's own running heads, verified to name the drug in its body text. — SOURCE EDITION: Plumb's Veterinary Drug Handbook — ISBN 9781394172207, https://openlibrary.org/isbn/9781394172207. Oclacitinib is used in dogs for Allergic/atopic dermatitis (pruritus control). Routes documented in dogs: PO. A typical adult dog weighs 2.00–80.00 kg. ExoticRx lists 1 cited dose rule for Oclacitinib in dogs, drawn from published veterinary references. Verify against current literature before clinical use.
US trade names: Apoquel
| Route | Dose | Frequency | Duration | Indication | Evidence | Source |
|---|---|---|---|---|---|---|
| PO | 0.4–0.6 mg/kg | q12h x 14 days, then q24h | Long-term maintenance at q24h |
| Allergic/atopic dermatitis (pruritus control) |
| Strong |
| APOQUEL - Oclacitinib Maleate Tablet, Coated [US Product Label for Dogs]. Kalamazoo, MI: Zoetis Inc.; 2020. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a39a0298-6453-4c21-a3b0-01c1a52a109b — Verified against Plumb's Veterinary Drug Handbook, 10th Ed, p.976 (2026-08-01). — Plumb's 10th ed (held) printed p.947, Oclacitinib monograph spanning p.947-948; page located 2026-08-05 from the book's own running heads, verified to name the drug in its body text. — SOURCE EDITION: Plumb's Veterinary Drug Handbook — ISBN 9781394172207, https://openlibrary.org/isbn/9781394172207 |
Every held source for this drug and species, as printed. Where they differ, both are shown — the choice is yours, not ours.
| Dose (mg/kg) | Route | Source | As printed |
|---|---|---|---|
| 0.4–0.6 | PO | BSAVA Small Animal Formulary, 10th ed — Part A (Canine and Feline)p.305 | 0.4-0.6 mg/kg p.o. q12h for 14 days, then q24h for maintenance. |
Figures are transcribed from the cited page or table of each held edition and are shown for reference only. They are not dose recommendations, they do not feed the calculator, and none has been reviewed by a veterinarian.
Need the exact dose for your patient?
These ranges are per kg. Enter your dog's weight to get the precise dose and draw-up volume — unit and concentration math done for you.
Selectively inhibits JAK1 (and to lesser extent JAK3), blocking signaling of itch and inflammation cytokines (IL-31, IL-4, IL-13) involved in allergic dermatitis.
Dogs only (not cats). Rapid onset of anti-pruritic effect (within 4h). Not for use under 12 months age. Immunosuppression risk — not recommended with concurrent immunosuppressives. May increase susceptibility to demodicosis and infections.
Species-specific contraindications and adverse-reaction reports for dogs may differ from canine / feline reference data — consult the primary citations listed with each rule.
Oclacitinib dose range in dogs, with cited source references: PO 0.4–0.6 mg/kg q12h x 14 days, then q24h. Reference ranges from cited sources — verify against current literature before clinical use.
Documented routes for Oclacitinib in dogs: PO.
Cited course lengths for Oclacitinib in dogs include: Long-term maintenance at q24h. Duration depends on the indication — match it to the specific dose rule in the table above.
Oclacitinib is indicated in dogs for: Allergic/atopic dermatitis (pruritus control).
These are general warnings for Oclacitinib across species; consult the dog dosing table above for species-specific guidance. Dogs only (not cats). Rapid onset of anti-pruritic effect (within 4h). Not for use under 12 months age. Immunosuppression risk — not recommended with concurrent immunosuppressives. May increase susceptibility to demodicosis and infections.
Why a species-specific page? Oclacitinib pharmacokinetics differ across species: dose ranges, intervals, and route preferences are not interchangeable. Cross-extrapolation from canine doses is unsafe in dogs — the rules above are the citations specific to this species, not generic recommendations.
Sourced from published veterinary references; awaiting credentialed clinical reviewer. See our editorial process. Reference only — not veterinary advice.